According to Quest Diagnostics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 12.8793. At the end of 2021 the company had a P/E ratio of 10.9.
Year | P/E ratio | Change |
---|---|---|
2021 | 10.9 | -3.03% |
2020 | 11.2 | -33.04% |
2019 | 16.8 | 8.69% |
2018 | 15.4 | -11.69% |
2017 | 17.5 | -13.01% |
2016 | 20.1 | 39.08% |
2015 | 14.5 | -17.42% |
2014 | 17.5 | 83.14% |
2013 | 9.56 | -42.74% |
2012 | 16.7 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() LabCorp LH | 11.4 | -11.13% | ๐บ๐ธ USA |
![]() Translate Bio
TBIO.defunct | N/A | N/A | ๐บ๐ธ USA |
![]() Psychemedics PMD | -14.4 | -211.69% | ๐บ๐ธ USA |
![]() NeoGenomics
NEO | -14.1 | -209.11% | ๐บ๐ธ USA |
![]() Qiagen QGEN | 24.9 | 93.67% | ๐ณ๐ฑ Netherlands |
![]() Enzo Biochem ENZ | -4.95 | -138.45% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.